• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.58% Nasdaq Up1.42%

    More On SHP.L

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Shire plc (SHP.L)

    -LSE
    4,641.00 Up 119.00(2.63%) 9:15AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Shire plc
    5 Riverwalk
    Citywest Business Campus
    Dublin, 24
    Ireland - Map
    Phone: 353 1 429 7700
    Website: http://www.shire.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:5,338

    Business Summary 

    Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Shire plc

    Key Executives 
     PayExercised
    Dr. Flemming Ornskov M.D., MBA, MPH, 56
    Managing Director, Chief Exec. Officer and Director
    3.40MN/A
    Mr. James Bowling ,
    Interim Chief Financial Officer, Sr. VP and Group Financial Controller
    N/AN/A
    Ms. Marianne Jackson ,
    Head of Global Commercial Operations
    N/AN/A
    Mr. William Ciambrone ,
    Head of Technical Operations
    N/AN/A
    Mr. Jeff Poulton ,
    Head of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.